how are glp-1 drugs made and Eating Disorders: A Hidden Risk in the Weight Loss Revolution – The Chicago Council on Science and Technology Schematic representation of production of

Lega IC, Lipscombe LL

Shaobo Ding, [email protected] These authors have contributed equally to this work This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

Visualization: pela Volanek

At the American Diabetes Association (ADA) 2025 conference: Eli Lilly presented bimagrumab plus semaglutide for improved muscle retention

Glucagon-like peptide-1 (GLP-1) receptor agonists, a new class of drugs sold under names such as Ozempic, Wegovy, and Zepbound, are soaring in popularity for their ability to achieve and sustain substantial weight loss and improve cardiometabolic health